Open access | Short Communication

Navigating Drug Delivery Issues: Challenges and Solutions

Bao Chai[*]

Department of Medical Sciences, California University, USA

INTRODUCTION

Drug delivery is a critical aspect of healthcare that ensures the effective administration of medications to patients. It plays a pivotal role in the success of medical treatments and therapies. However, the field of drug delivery is not without its challenges. Various issues can hinder the efficient and safe delivery of drugs, impacting patient outcomes and healthcare costs. In this article, we will explore some of the key drug delivery issues and discuss potential solutions to overcome them.

DESCRIPTION

One of the foremost challenges in drug delivery is patient compliance. Many patients fail to adhere to their prescribed medication regimens, either by missing doses or discontinuing treatment altogether. This non-compliance can lead to suboptimal therapeutic outcomes and increased healthcare costs. To address this issue, healthcare providers and pharmaceutical companies are exploring strategies such as developing long-acting formulations, utilizing mobile health apps for reminders, and offering educational programs to improve patient understanding and engagement. The effectiveness of a drug greatly depends on its ability to be absorbed and reach the target site within the body. Poor absorption and low bioavailability can render even the most promising drugs ineffective. These issues often arise due to the drug's physicochemical properties or the patient's physiology. To enhance absorption, drug developers are working on nanotechnology-based drug carriers, prodrugs, and innovative formulation techniques that improve solubility and stability, ultimately boosting bioavailability and efficacy. Some drugs are highly susceptible to degradation when exposed to environmental factors such as heat, light, or moisture. This poses a significant challenge, particularly in areas with unstable climatic conditions. Proper storage and transportation are crucial to maintain the integrity of pharmaceutical products. Pharmaceutical companies are investing in advanced packaging technologies and developing more stable drug formulations to mitigate degradation risks during storage and transportation. Antibiotic resistance is a growing global concern. The overuse and misuse of antibiotics have led to the emergence of drug-resistant strains of bacteria, making it difficult to treat infections. The development of new antibiotics and antimicrobial agents is essential to combat this issue. Researchers are exploring alternative treatment options, such as phage therapy and combination therapy, to address antibiotic resistance and ensure effective drug delivery. In some cases, drugs are needed to act specifically at certain target sites within the body. Achieving this level of precision in drug delivery can be challenging. Systemic administration often results in off-target effects and potential toxicity. Advances in nanomedicine and targeted drug delivery systems are improving the precision of drug administration, reducing side effects, and enhancing therapeutic outcomes. These systems include nanoparticles, liposomes, and monoclonal antibodies designed to deliver drugs directly to the intended site [1-4]. The pharmaceutical industry faces stringent regulatory requirements and approval processes, which can be time-consuming and costly.

CONCLUSION

These hurdles may delay the introduction of new drugs and innovations to the market, affecting patient access to cutting-edge therapies. Efforts to streamline regulatory pathways and foster collaboration between industry stakeholders, regulatory bodies, and healthcare providers are essential for expediting the approval of new drug delivery technologies and therapies.

ACKNOWLEDGEMENT

CONFLICT OF INTEREST

The author's declared that they have no conflict of interest.

REFERENCES

1. Gorter, Thomas M (2016) "Right ventricular function after acute myocardial infarction treated with primary percutaneous coronary intervention (from the glycometabolic intervention as adjunct to primary percutaneous coronary

intervention in ST-segment elevation myocardial infarction III trial)." Am J cardiol 118(3): 338-344.

2. Kanar BG, Tigen MK, Sunbul M, Cincin A, Atas H, et al. (2018) The impact of right ventricular function assessed by 2-dimensional speckle tracking echocardiography on early mortality in patients with inferior myocardial infarction. Clin Cardiol 41(3): 413-418.

3. Zavaleta NS, Velasquez PJ, Nieto RG, Camacho GC, Pinot ES, et al. (2022) Right atrial and right ventricular function assessed by speckle tracking in patients with inferior myocardial infarction. Rev Cardiovas Med 23(4): 123.

4. Anavekar NS, Skali H, Bourgoun M (2008) Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). Am J Cardiol 101:607-612.